Inflammatory Bowel Disease

Feline inflammatory bowel disease (IBD) is one of the most common causes of chronic vomiting and diarrhea in cats, representing a group of idiopathic, immunologically mediated gastrointestinal (GI) disorders characterized by persistent or recurrent GI signs and histologic mucosal inflammation [2][5]. The disease is defined by the infiltration of inflammatory cells into the lamina propria of the GI tract, with the small intestine most frequently affected, though inflammation may involve any segment from stomach to colon [2]. IBD in cats exists on a clinical and histological spectrum that can be difficult to distinguish from intestinal small cell lymphoma (SCL), a distinction that carries important diagnostic and long-term management implications [1]. Affected cats may also concurrently develop inflammation of the pancreas and liver—a triad known as "feline triaditis"—underscoring the systemic inflammatory nature of the condition [3].

The precise etiology of feline IBD remains incompletely understood, but current evidence supports a multifactorial origin involving interactions between the host immune system, intestinal microbiota, genetic predisposition, and environmental or dietary antigens [2].

Immune Dysregulation The central pathological mechanism is an inappropriate and sustained mucosal immune response, likely triggered by luminal antigens such as dietary proteins or commensal bacteria [2]. In healthy cats, immune tolerance to these antigens is maintained via regulatory T cell activity and mucosal barrier integrity. In IBD, this tolerance breaks down, leading to persistent activation of innate and adaptive immune pathways, recruitment of inflammatory cells (lymphocytes, plasma cells, eosinophils, neutrophils, or macrophages) into the lamina propria, and ongoing mucosal injury [2][5].

Microbiome Dysbiosis Alterations in the composition and diversity of the intestinal microbiome (dysbiosis) are strongly implicated in the development and perpetuation of GI inflammation [8]. Shifts in the balance of beneficial versus potentially pathogenic bacteria disrupt the normal homeostatic signals that regulate immune tone at the mucosal surface [8].

Dietary Antigens Food hypersensitivity or intolerance may initiate or amplify mucosal inflammation, as evidenced by the positive clinical response some cats show to novel protein or hydrolyzed protein diets [2][5].

Genetic Factors Certain breeds, such as Siamese and other Oriental breeds, appear over-represented, suggesting a heritable component to susceptibility [2].

Histological Classification IBD is classified by the predominant inflammatory cell infiltrate: lymphoplasmacytic IBD (most common), eosinophilic IBD, neutrophilic IBD, and granulomatous IBD. Each subtype may reflect different underlying immunological triggers and carries different therapeutic implications [2][5].

Relationship to Lymphoma A subset of feline IBD may represent a precursor lesion or exist on a continuum with intestinal small cell (low-grade) lymphoma, though this transition remains an active area of research [1]. Both share similar signaling abnormalities, making their differentiation challenging without advanced diagnostics such as immunohistochemistry or clonality testing [1].

Triaditis The anatomical proximity and shared portal venous drainage between the feline intestine, pancreas, and liver may predispose cats to concurrent multi-organ inflammation, known as triaditis, which complicates both the clinical presentation and management of IBD [3].

Diagnosing feline IBD requires systematic exclusion of other causes of chronic enteropathy (dietary intolerance, parasites, infectious disease, neoplasia) combined with histopathological confirmation [2][5].

History and Physical Examination A detailed dietary, travel, and treatment history is essential. Physical findings may include poor body condition, thickened intestinal loops, mesenteric lymphadenopathy, or signs of concurrent hepatopancreatic disease [4][5].

Feline Chronic Enteropathy Activity Index (FCEAI) A validated clinical scoring tool (FCEAI) exists to quantify disease activity in cats with chronic enteropathy, incorporating parameters such as attitude, appetite, vomiting frequency, stool consistency, weight loss, and serum albumin [4]. This index aids in objectively measuring treatment response.

Laboratory Diagnostics

Key laboratory indicators include:

• ·Complete Blood Count (CBC):
  • ·HCT (Hematocrit): May be low in cats with chronic disease, blood loss, or protein-losing enteropathy
  • ·WBC: Variable; eosinophilia supports eosinophilic IBD; neutrophilia may suggest secondary infection or concurrent pancreatitis
  • ·PLT (Platelets): Generally within reference range unless systemic inflammation is severe
• ·Serum Biochemistry:
  • ·ALB (Albumin): Often low; hypoalbuminemia is a hallmark of protein-losing enteropathy associated with severe IBD and is an important prognostic indicator [4]
  • ·GLOB (Globulins): May be elevated due to chronic antigenic stimulation
  • ·ALT (Alanine Aminotransferase): May be elevated if concurrent hepatic involvement (triaditis) is present [3]
  • ·TBIL (Total Bilirubin): May be elevated if cholangitis or hepatic disease coexists [3]
  • ·BUN/CREA: May be altered secondary to poor nutritional intake, muscle catabolism, or dehydration; not specific for IBD
• ·Cobalamin (Vitamin B12): Frequently low in cats with small intestinal IBD due to ileal malabsorption; considered an important marker of small intestinal dysfunction and is associated with poorer outcomes [2]
• ·Folate: May be elevated in proximal small intestinal disease or low in diffuse small intestinal disease
• ·TLI (Trypsin-Like Immunoreactivity): To rule out exocrine pancreatic insufficiency as a differential diagnosis
• ·fPLI (Feline Pancreatic Lipase Immunoreactivity): To assess for concurrent pancreatitis (triaditis) [3]

Fecal Examination Direct smear, flotation, and Giardia antigen testing are necessary to rule out parasitic infections prior to diagnosing idiopathic IBD [2][5].

Diagnostic Imaging

• ·Abdominal Ultrasound: Evaluates intestinal wall layering, thickness, and echogenicity; identifies mesenteric lymphadenopathy and changes in pancreatic or hepatic architecture [1][3]
• ·Survey Radiographs: Limited utility for IBD specifically but useful for ruling out obstruction or mass lesions

Endoscopy and Histopathology Definitive diagnosis of IBD requires histopathological evaluation of intestinal biopsies [1][2][5]. Endoscopy (gastroduodenoscopy, colonoscopy) allows direct mucosal visualization and targeted biopsy collection. Full-thickness surgical biopsies (via laparotomy or laparoscopy) offer superior tissue architecture for distinguishing IBD from lymphoma but carry higher procedural risk.

Differentiating IBD from Small Cell Lymphoma Lymphoplasmacytic IBD and intestinal SCL can be histologically indistinguishable on routine hematoxylin and eosin staining [1]. Ancillary tests including:

• ·Immunohistochemistry (IHC): CD3 (T-cell) vs. CD20/CD79a (B-cell) markers
• ·PARR (PCR for Antigen Receptor Rearrangement): Clonality testing to detect monoclonal lymphocyte populations

are required for definitive differentiation in ambiguous cases [1].

Treatment of feline IBD is multimodal, combining dietary management, immunosuppressive therapy, and nutritional supplementation, tailored to disease severity and histological subtype [2][5][6].

1. Dietary Management (First-Line) Dietary modification is often the first therapeutic step, particularly for cases where food-responsive enteropathy cannot yet be excluded:

• ·Novel protein diet: A single, novel protein source the cat has never previously been exposed to (e.g., rabbit, venison, duck)
• ·Hydrolyzed protein diet: Proteins enzymatically reduced in molecular weight to minimize antigen recognition
• ·A strict dietary trial of 4–6 weeks is recommended before assessing response [2][5]
• ·Highly digestible, low-fat diets may also help reduce antigenic load and GI workload [6]

2. Corticosteroids (Mainstay of Immunosuppressive Therapy) Glucocorticoids are the primary immunosuppressive treatment for confirmed IBD [2][5][6]:

• ·Prednisolone: Starting dose typically 1–2 mg/kg orally once or twice daily; gradually tapered over weeks to months once clinical remission is achieved. Note: Prednisolone is preferred over prednisone in cats due to limited hepatic conversion of prednisone to its active form.
• ·Budesonide: A locally acting glucocorticoid with high first-pass hepatic metabolism, resulting in fewer systemic side effects; may be preferable in cats prone to steroid adverse effects or with concurrent hepatic disease [6]

3. Additional Immunosuppressive Agents Reserved for steroid-refractory cases or as steroid-sparing agents [2][6]:

• ·Chlorambucil: Particularly useful in lymphoplasmacytic IBD refractory to steroids alone; also the treatment of choice for concurrent or suspected small cell lymphoma (typically combined with prednisolone as the "Leukeran protocol") [1][6]
• ·Metronidazole: Has both antimicrobial and immunomodulatory properties; useful as adjunctive therapy, particularly for large intestinal involvement or suspected dysbiosis [5][6]
• ·Azathioprine: Used in dogs but generally avoided in cats due to significant myelosuppression risk; not a first-choice option in feline IBD

4. Cobalamin (Vitamin B12) Supplementation Cats with documented hypocobalaminemia require parenteral or oral supplementation [2]:

• ·Injectable cyanocobalamin or hydroxocobalamin (250 µg subcutaneously once weekly for 4–6 weeks, then monthly) is traditionally used
• ·Oral cobalamin supplementation is an increasingly accepted and practical alternative

5. Probiotics and Microbiome Support Modulation of intestinal microbiota through probiotic supplementation may provide adjunctive benefit, given the evidence for dysbiosis in feline IBD [8]. Evidence is currently limited but supports cautious use as part of a comprehensive management plan.

6. Management of Concurrent Triaditis When IBD coexists with pancreatitis and cholangitis, treatment must address all three components simultaneously [3]. Ursodeoxycholic acid may be used for cholangitic liver disease; anti-nausea medications (maropitant, ondansetron) are important supportive agents; and adequate analgesia should be provided if pancreatitis pain is suspected [3].

7. Supportive Care

• ·Antiemetics (maropitant, ondansetron) for symptom management
• ·Appetite stimulants (mirtazapine) in anorectic cats
• ·Fluid therapy for dehydrated patients
• ·Assisted enteral nutrition (nasogastric or esophagostomy tube) in severely malnourished cats

The prognosis for cats with IBD is generally favorable to good with appropriate long-term management, though complete cure is uncommon and most cats require ongoing medical therapy [2][5].

General Prognosis The majority of cats with IBD can be successfully managed with dietary modification and/or immunosuppressive therapy, with a good quality of life achievable in most cases [5]. Clinical remission is attainable in many patients, though relapse upon drug tapering is common and long-term or lifelong treatment is often necessary [2].

Prognostic Factors

• ·Serum albumin: Hypoalbuminemia at the time of diagnosis is associated with a more guarded prognosis and severe disease [4]
• ·Cobalamin status: Persistent hypocobalaminemia is associated with poorer outcomes; response to cobalamin supplementation is generally favorable [2]
• ·Disease severity score: The FCEAI has been validated as a useful tool for tracking treatment response; higher baseline scores reflect greater disease burden [4]
• ·Histological subtype: Eosinophilic IBD generally carries a more favorable prognosis than lymphoplasmacytic IBD; neutrophilic and granulomatous forms tend to be more severe and less responsive [2][5]
• ·Concurrent triaditis: Multi-organ involvement increases clinical complexity and is associated with a more guarded short-term prognosis, particularly when all three organs are severely affected [3]

IBD vs. Small Cell Lymphoma An important consideration is distinguishing IBD from intestinal SCL, as the two conditions have similar but not identical prognoses [1]. Cats with SCL treated with chlorambucil and prednisolone have reported median survival times of approximately 2–3 years in some case series. Cats with pure IBD may have an even more favorable long-term outlook with appropriate management [1]. Some clinicians argue that because treatment protocols and prognosis overlap significantly, aggressive diagnostics to achieve absolute distinction may not always change clinical outcomes [1].

Mortality IBD itself is rarely directly fatal when treated appropriately; however, severe, refractory, or complicated disease (e.g., with protein-losing enteropathy, cachexia, or progression to high-grade lymphoma) significantly worsens the prognosis. Data on precise mortality rates specific to feline IBD are limited in the current peer-reviewed literature [1][2].

There are currently no vaccines available for feline IBD, and no definitive preventive strategies have been established given the incompletely understood, multifactorial etiology of the disease [2].

Dietary Management

• ·Feeding a high-quality, consistent diet with limited ingredient changes may reduce chronic dietary antigen exposure
• ·Avoiding frequent dietary switching may help minimize the risk of developing food sensitivities that can contribute to or exacerbate intestinal inflammation [2][5]

Parasite Control

• ·Routine intestinal parasite screening and prophylactic anthelmintic treatment reduce the likelihood of parasitic enteropathy mimicking or triggering IBD [2][5]

Microbiome Health

• ·Judicious use of antibiotics (to avoid dysbiosis) and consideration of probiotic supplementation may support a healthy intestinal microbial balance [8]
• ·Minimizing unnecessary antibiotic courses helps preserve commensal microbial diversity

Early Veterinary Evaluation

• ·Cats exhibiting chronic or recurrent GI signs (vomiting, diarrhea, weight loss) should receive early veterinary evaluation to allow diagnosis and management before disease progression [5]
• ·Routine wellness monitoring, including body weight, body condition scoring, and screening blood work, facilitates early detection of hypoalbuminemia or cobalamin deficiency in at-risk cats [4]

Stress Reduction Environmental stress is recognized as a contributing factor to GI dysfunction in cats; optimizing the home environment (litter box hygiene, reduced inter-cat conflict, environmental enrichment) may support GI health, though direct evidence linking stress reduction to IBD prevention in cats is limited.